Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Companies’ complementary strengths in data and cloud technology to improve healthcare efficiency and patient outcomes
T3 Pharmaceuticals AG, a Basel-based company focusing on immuno-oncology, closes its second financing round of over 12M CHF with existing investors joined by Boehringer Ingelheim Venture Fund and Reference Capital SA.
Led by ARTIS Ventures, Funding will Drive Further Research and Commercialization of Eko’s Machine Learning Platform
Summit Therapeutics plc announces that it will host a research and development day for investors and media on 7 October 2019 from 8am-12pm EDT in New York City.
Company inaugurates its new production unit for active pharmaceutical ingredients, the cornerstone of Provepharm’s development
H.E.L. Group Ltd, a global manufacturer of innovative laboratory tools for process optimization, safety and scale-up, announced the appointment of Louise Madden as Chief Executive Officer (CEO).
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc that Amphion has agreed to amend the terms of the Loan Facility with Amphion’s debt provider.
Ergomed plc, a company focused on providing specialised services to the global pharmaceutical industry, announces its unaudited interim results for the six months ended 30 June 2019.
Tacalyx announced that it has successfully secured €7 million in seed funding.
Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), provides a business update for the last twelve months.